StockNews.AI
ONC
StockNews.AI
104 days

BeiGene Announces First Quarter 2025 Financial Results and Business Updates

1. BeiGene reported first quarter 2025 GAAP profitability. 2. BRUKINSA leads U.S. market in new CLL patient starts.

Earnings
-2.66%Current Return
VS
+1.87%S&P 500
$240.8905/07 06:14 AM EDTEvent Start
$234.4805/08 11:49 AM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

GAAP profitability and leadership in CLL suggests steady revenue growth potential, similar to historical peaks after profitability announcements.

How important is it?

Profitable quarters tend to attract investor interest; maintaining leadership in CLL enhances market position and investor confidence.

Why Short Term?

Positive financial results may drive immediate investor interest and stock performance for ONC.

Related Companies

BRKBABBVGENE
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025. “We delivered another exceptional quarter, achieving our first quarter of GAAP profitability with continued global revenue growth. In the U.S., BRUKINSA remains the leader in new chronic lymphocytic leukemia (CLL) patient starts across all line.

Related News